About Company
Center of Molecular Research (CMR) – one of the leading global suppliers of nuclear medicine products. CMR Group was established in 2001 and during more than 20 years has been specialized in the development, production, distribution of isotopes, Iyophizates, reagents, peptides and a wide range of other products for radionuclide diagnostic and therapy.
Modern THERANOSTIC trend
In the last few years, Theranostic technologies based on 17Lu and 28Ac have been rapidly developed in the world of nuclear medicine. Most of them are used together with #Ga and “F- Labelled compounds for PET (PET/CT) diagnostics which seriously limits possibilities for hospitals which have SPECT equipment and still not involved into PET (PET/CT) diagnostics.
Our Goal
CMR team together with our partners focused on the goal to develop omTc radiopharmaceutical precursor (Cold Kit) with a PSMA-targeting molecule to provide prostate cancer diagnostic possibilities for medical centers equipped with SPECT/CT only.
After several years of working together we are pleased to announce that 99mTc-PSMA-11 Cold Kit has been successfully developed as Theranostic pair for Lu-177 therapy. We named it TECHNOPROST, the product is available for commercial deliveries and is already in regular use for SPECT diagnostics of prostate cancer.
Product Overview
- TECHNOPROST is a complex of Technetium-99m with PSMA-11 ligand. The radiopharmaceutical is used for radioligand SPECT/CT diagnostics of prostate cancer. 90mTc-PSMA-111 is characterized by favorable pharmacokinetics, high and prolonged accumulation in tumors and metastases, rapid elimination from the body, resulting in high values of the differential accumulation coefficient (ratio of the radioactive isotope concentration in the target organ to the concentration in the whole body) and qualitative visualization of small tumor foci.
- Market Authorization Tc-PSMA-11 has Market Authorization # DV/M 04244/09/22 under trade name TECHNOPROST.
- PATENT TECHNOPROST has been patented (# FAP 02118): <Method for obtaining radiopharmaceutical SenTc-PSMA-11 for the diagnosis of prostate cancer.
Indications:
TECHNOPROST, #=Tc is a Cold Kit for preparation of solution for intravenous administration. The radiopharmaceutical is used for male adults for SPECT/CT diagnostics of prostate cancer.
Preparation (General Information):
TECHNOPROST is designed with maximum comfort for users as: <Shake it and Use it>
- ADD Tc-99m to prepare TECHNOPROST, *=Tc radiopharmaceutical, just add 1 to 5 ml of sodium pertechnetate (depending on medical case), **”Tc solution with radioactive concentration 370-1850 MBq/ml from the %=Tc-generator with a syringe into a vial.
- SHAKE IT Shake the vial until the Iyophilizate is completely dissolved (about 1 minute only).
- USE IT TECHNOPROST, ##Tc radiopharmaceutical is ready to use and can be injected intravenously.
